May 17 | News
NEW YORK (AP) — Alkermes PLC said today it took a larger loss in its fiscal fourth quarter after it acquired a drug technology business and took a one-time charge related to research and development.
|
Feb 3 | News
Alkermes PLC's fiscal third-quarter loss widened as operating expenses ballooned compared to the previous year's quarter, before the company had completed its acquisition of Elan Corp.'s drug technology business.
|
May 13 2011 | News
Paladin Labs Inc., a Canadian specialty pharmaceutical
company, today announced that they have entered into a licensing and
distribution agreement under which Paladin has been granted exclusive Canadian
rights from an affiliate of Elan Corporation, plc to market and sell, upon
regulatory approval, Elan's controlled release hydrocodone product for the
treatment of moderate to severe pain.
|
May 9 2011 | News
Alkermes, Inc. and Elan Corporation, plc today announced the
execution of a definitive agreement under which Alkermes will merge with Elan
Drug Technologies (EDT), the profitable, world-class drug formulation and
manufacturing business unit of Elan, in a cash and stock transaction currently
valued at approximately $960 million.
|
Apr 20 2011 | News
Elan Corp. said Wednesday it turned a first-quarter profit,
helped by a legal settlement, sales growth for the multiple sclerosis treatment
Tysabri and lower expenses.
|
Mar 1 2011 | News
BOSTON (AP) — A U.S. subsidiary of Irish drugmaker
Elan Corp. PLC has pleaded guilty to misdemeanor violation of the federal Food
Drug and Cosmetic Act over the improper marketing of the epilepsy drug
Zonegran.
|
Feb 25 2011 | News
Elan Corporation plc and Celgene Corporation, today
announced that Elan subsidiary Elan Pharma International Limited has entered
into a settlement and license agreement with Celgene Corporation resolving the
patent infringement litigation involving ABRAXANE(R). Elan initiated legal
action in 2006 against Abraxis BioScience, Inc.
|
Feb 23 2011 | News
Elan and PPD, Inc. today announced they have formed a
global business collaboration focused on the advancement, progression and
execution of Elan's development portfolio.
|
Dec 22 2010 | News
Biogen
Idec and Elan
Corporation, plc have
submitted a supplemental Biologics License Application (sBLA) to the FDA and a Type II Variation to the
European Medicines Agency (EMA) to request review and approval to update
the respective TYSABRI Prescribing Information and Summary of Product
Characteristics.
|
Dec 16 2010 | News
Irish pharmaceutical manufacturer Elan
Corporation PLC and its U.S.
subsidiary have agreed to pay more than $203 million for alleged illegal
promotion of the epilepsy drug Zonegran
|